Literature DB >> 11257353

Transmission blocking malaria vaccines.

R Carter1.   

Abstract

Transmission blocking vaccines (TBVs) against malaria are intended to induce immunity against the stages of the parasites which infect mosquitoes so that TBV-immunised individuals cannot transmit malaria. As malarial infections are transmitted mainly within a few hundreds of meters from an infectious human source, TBVs used within in a community would protect the immediate neighbourhood of the vaccinated individuals. TBVs against the two major species of human malaria, Plasmodium falciparum and P. vivax, are under development. Candidate TBV constructs for both Plasmodium species have been successfully tested in animal systems and testing is in progress with clinical grade material in humans.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11257353     DOI： 10.1016/s0264-410x(00)00521-1

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  74 in total

1.  Disruption of Plasmodium falciparum development by antibodies against a conserved mosquito midgut antigen.

Authors:  Rhoel R Dinglasan; Dario E Kalume; Stefan M Kanzok; Anil K Ghosh; Olga Muratova; Akhilesh Pandey; Marcelo Jacobs-Lorena
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-02       Impact factor: 11.205

2.  Expression, immunogenicity, histopathology, and potency of a mosquito-based malaria transmission-blocking recombinant vaccine.

Authors:  D K Mathias; J L Plieskatt; J S Armistead; J M Bethony; K B Abdul-Majid; A McMillan; E Angov; M J Aryee; B Zhan; P Gillespie; B Keegan; A R Jariwala; W Rezende; M E Bottazzi; D G Scorpio; P J Hotez; R R Dinglasan
Journal:  Infect Immun       Date:  2012-02-06       Impact factor: 3.441

3.  Markedly enhanced immunogenicity of a Pfs25 DNA-based malaria transmission-blocking vaccine by in vivo electroporation.

Authors:  Ralph LeBlanc; Yessika Vasquez; Drew Hannaman; Nirbhay Kumar
Journal:  Vaccine       Date:  2007-11-20       Impact factor: 3.641

Review 4.  Plasmodium p25 and p28 surface proteins: potential transmission-blocking vaccines.

Authors:  Ajay K Saxena; Yimin Wu; David N Garboczi
Journal:  Eukaryot Cell       Date:  2007-06-08

5.  Sequence polymorphisms in Pvs48/45 and Pvs47 gametocyte and gamete surface proteins in Plasmodium vivax isolated in Korea.

Authors:  Mi Kyung Woo; Kyeong Ah Kim; JuYeon Kim; Jun Seo Oh; Eun Taek Han; Seong Soo A An; Chae Seung Lim
Journal:  Mem Inst Oswaldo Cruz       Date:  2013-05       Impact factor: 2.743

6.  Induction of Plasmodium falciparum transmission-blocking antibodies in nonhuman primates by a combination of DNA and protein immunizations.

Authors:  Cevayir Coban; Mario T Philipp; Jeanette E Purcell; David B Keister; Mobolaji Okulate; Dale S Martin; Nirbhay Kumar
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

Review 7.  Malaria: progress, perils, and prospects for eradication.

Authors:  Brian M Greenwood; David A Fidock; Dennis E Kyle; Stefan H I Kappe; Pedro L Alonso; Frank H Collins; Patrick E Duffy
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

Review 8.  Murine infection models for vaccine development: the malaria example.

Authors:  Kai Matuschewski
Journal:  Hum Vaccin Immunother       Date:  2012-12-18       Impact factor: 3.452

9.  Baculovirus-vectored multistage Plasmodium vivax vaccine induces both protective and transmission-blocking immunities against transgenic rodent malaria parasites.

Authors:  Masanori Mizutani; Mitsuhiro Iyori; Andrew M Blagborough; Shinya Fukumoto; Tomohiro Funatsu; Robert E Sinden; Shigeto Yoshida
Journal:  Infect Immun       Date:  2014-08-04       Impact factor: 3.441

Review 10.  Young lives lost as B cells falter: what we are learning about antibody responses in malaria.

Authors:  Silvia Portugal; Susan K Pierce; Peter D Crompton
Journal:  J Immunol       Date:  2013-04-01       Impact factor: 5.422
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.